Ernexa Therapeutics (ERNA) vs Kairos Pharma (KAPA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Ernexa Therapeutics is the larger company by market cap ($2.3 million vs $2.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ERNA | KAPA |
|---|---|---|
| Share price | $1.36 | $0.4359 |
| Market cap | $2.30M | $2.04M |
| 1-day change | -16.56% | -4.62% |
| EPS (TTM) | $-11.22 | $-2.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-14.08M | $-5.45M |
| 52-week high | $37.50 | $7.28 |
| 52-week low | $1.35 | $0.381 |
| Distance from 52-week high | -96.37% | -94.01% |
| Analyst consensus | none | none |
| Avg. price target upside | +2105.88% | +11141.11% |
| Average volume | 43.90K | 364.25K |
| Shares outstanding | 1.69M | 4.69M |
| Employees | 5 | 1 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Ernexa Therapeutics
ERNA stock →Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Kairos Pharma
KAPA stock →Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
ERNA vs KAPA FAQ
Which is bigger, Ernexa Therapeutics or Kairos Pharma?
Ernexa Therapeutics (ERNA) is larger, with a market capitalization of $2.30M compared with $2.04M for Kairos Pharma (KAPA).
Are Ernexa Therapeutics and Kairos Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.